source
- STAT+: Astellas treatment offers new hope to a devastated rare disease communityAlzheimer's drug rollout letdown, a China-based heart drug startup, and more biotech news from The ReadoutSTAT · 2mo ago↗ source
- Inhibrx delivers ‘differentiated’ cancer drug data; Fractyl starts diabetes gene therapy trialInhibrx, the subject of recent buyout rumors, showed its drug might enhance the effects of Keytruda. Elsewhere, Capricor sued its cell therapy partner and Argenx got a revenue boost.BioPharma Dive · 2mo ago↗ source
- Braveheart Bio's Hengrui-licensed cardiac drug scores second clinical winBraveheart Bio said Monday that the heart muscle therapy it licensed from China’s Jiangsu Hengrui Pharmaceuticals has succeeded in a mid-stage trial for the same condition in which Cytokinetics rec…